|
|
FAculty directory
Back to alphabetical index

Mary "Cissy" van den berg-Wolf, MD, FACP
Clinical Professor (Adjunct), Medicine
Deputy Director, Comprehensive Temple HIV Program
Telephone: 215-707-1800
Fax: 215-707-3644
Email: mvan@temple.edu
Department of Medicine, Section of General Internal Medicine
BS, University of Michigan, Ann Arbor, MI, 1975
MD, Georgetown University School of Medicine, Washington, D.C., 1979
Internship, Temple University Hospital, Philadelphia, PA, 1979-1981
Internship, Free University of Amsterdam, Netherlands, 1982-1985
Return to top
- HIV Medicine
- General Internal Medicine
Return to top
- HIV clinical trials
- Hyperlipidemia
- HIV
Return to top
Internal Medicine
Return to top
professional affiliations: |
- Society of General Internal Medicine
- Philadelphia College of Physicians
- American Academy of HIV Medicine
- Member HIVMA (IDSA)
- Member American College of Physicians
Return to top
Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)
19635261. van den Berg-Wolf M, Tedaldi EM, Therapeutic strategies for chronic hepatitis B virus infection in 2008-optimum dosing lamivudine challenged for HIV-1 infected patients. Am J Med 122:8(e11)2009 Aug
18977721. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD, Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 9:5(324-36)2008 Sep-Oct
18176329. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M, Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 47:4(441-8)2008 Apr 1
17174704. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M, A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 368:9553(2125-35)2006 Dec 16
15682349. MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M, Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clin Trials 5:6(361-70)2004 Nov-Dec
15668873. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M, Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40:3(468-74)2005 Feb 1
11306155. MacArthur RD, Chen L, Mayers DL, Besch CL, Novak R, van den Berg-Wolf M, Yurik T, Peng G, Schmetter B, Brizz B, Abrams D, The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials 22:2(176-90)2001 Apr
2296325. Buijs L, Pietersz RN, van den Berg-Wolf MG, Reesink HW, ten Veen JH, [Treatment of AIDS patients with zidovudine] Ned Tijdschr Geneeskd 134:2(71-5)1990 Jan 13
3140839. van den Berg-Wolf MG, Pietersz RN, Reesink HW, ten Veen JH, Brutel de la Riviere G, Complete remission of an AIDS-related B-cell lymphoma with one course of chemotherapy followed by zidovudine treatment. AIDS 2:4(319-20)1988 Aug
2962350. Van den Berg-Wolf MG, Kootte AM, Weening JJ, Paul LC, Recurrent hemolytic uremic syndrome in a renal transplant recipient and review of the Leiden experience. Transplantation 45:1(248-51)1988 Jan
Return to top
|
|